niacinamide has been researched along with Mucositis in 7 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Mucositis: An INFLAMMATION of the MUCOSA with burning or tingling sensation. It is characterized by atrophy of the squamous EPITHELIUM, vascular damage, inflammatory infiltration, and ulceration. It usually occurs at the mucous lining of the MOUTH, the GASTROINTESTINAL TRACT or the airway due to chemical irritations, CHEMOTHERAPY, or radiation therapy (RADIOTHERAPY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "As a group of European nurses familiar with treating patients with renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC) using targeted/chemo- therapies, we aimed to review strategies for managing adverse events (AEs) associated with one targeted therapy, sorafenib." | 8.88 | Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group. ( Boers-Doets, C; Chrysou, M; Edmonds, K; Hull, D; Koldenhof, J; Molassiotis, A; Spencer-Shaw, A, 2012) |
| "As a group of European nurses familiar with treating patients with renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC) using targeted/chemo- therapies, we aimed to review strategies for managing adverse events (AEs) associated with one targeted therapy, sorafenib." | 4.88 | Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group. ( Boers-Doets, C; Chrysou, M; Edmonds, K; Hull, D; Koldenhof, J; Molassiotis, A; Spencer-Shaw, A, 2012) |
| "Sorafenib is an orally active multikinase inhibitor approved for the treatment of mRCC." | 2.77 | Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment. ( Alonso, S; Calabrò, F; Caristo, R; Catalano, A; Cerbone, L; Di Paola, ED; Leone, A; Mancuso, A; Messina, C; Sternberg, CN; Vigna, L; Zivi, A, 2012) |
| "Metastatic renal cell carcinoma (mRCC) has historically been refractory to cytotoxic and hormonal agents." | 1.43 | Sunitinib in metastatic renal cell carcinoma (mRCC): a developing country experience. Do our patients behave differently than the Western patients? ( Aziz, SA; Bhat, GM; Changal, KH; Lone, AR; Mir, MH, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Castellano, D | 1 |
| Capdevila, J | 1 |
| Sastre, J | 1 |
| Alonso, V | 1 |
| Llanos, M | 1 |
| García-Carbonero, R | 1 |
| Manzano Mozo, JL | 1 |
| Sevilla, I | 1 |
| Durán, I | 1 |
| Salazar, R | 1 |
| Abdel-Rahman, O | 1 |
| Fouad, M | 1 |
| Liu, X | 1 |
| Lorusso, P | 1 |
| Mita, M | 1 |
| Piha-Paul, S | 1 |
| Hong, DS | 1 |
| Fu, S | 1 |
| McQuinn, L | 1 |
| Asatiani, E | 1 |
| Doyle, LA | 1 |
| Chen, HX | 1 |
| Hess, KR | 1 |
| Kurzrock, R | 1 |
| Naing, A | 1 |
| Kaymakcalan, MD | 1 |
| Xie, W | 1 |
| Albiges, L | 1 |
| North, SA | 1 |
| Kollmannsberger, CK | 1 |
| Smoragiewicz, M | 1 |
| Kroeger, N | 1 |
| Wells, JC | 1 |
| Rha, SY | 1 |
| Lee, JL | 1 |
| McKay, RR | 1 |
| Fay, AP | 1 |
| De Velasco, G | 1 |
| Heng, DY | 1 |
| Choueiri, TK | 1 |
| Mir, MH | 1 |
| Changal, KH | 1 |
| Aziz, SA | 1 |
| Bhat, GM | 1 |
| Lone, AR | 1 |
| Edmonds, K | 1 |
| Hull, D | 1 |
| Spencer-Shaw, A | 1 |
| Koldenhof, J | 1 |
| Chrysou, M | 1 |
| Boers-Doets, C | 1 |
| Molassiotis, A | 1 |
| Mancuso, A | 1 |
| Di Paola, ED | 1 |
| Leone, A | 1 |
| Catalano, A | 1 |
| Calabrò, F | 1 |
| Cerbone, L | 1 |
| Zivi, A | 1 |
| Messina, C | 1 |
| Alonso, S | 1 |
| Vigna, L | 1 |
| Caristo, R | 1 |
| Sternberg, CN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Study of Temsirolimus in Combination With Metformin in Patients With Advanced Cancers[NCT01529593] | Phase 1 | 87 participants (Actual) | Interventional | 2012-03-26 | Active, not recruiting | ||
| Phase I Dose Escalation Trial of MEK1/2 Inhibitor MSC1936369B Combined With Temsirolimus in Subjects With Advanced Solid Tumors[NCT01378377] | Phase 1 | 33 participants (Actual) | Interventional | 2011-05-27 | Terminated (stopped due to The trial was stopped due to the toxicities observed with the combination of pimasertib and temsirolimus.) | ||
| Phase I Study of IMC-A12 (NSC# 742460) in Combination With Temsirolimus CCI-779 (NSC# 683864) in Patients With Advanced Cancers[NCT00678769] | Phase 1 | 72 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
DLT was defined as any of the following toxicities graded as per National Cancer Institute (NCI) common terminology criteria for adverse events (NCI CTCAE v4.0) encountered within cycle 1 of treatment at any dose level and judged not to be related to the underlying disease or concomitant medications. A treatment emergent adverse event (TEAE) of potential clinical significance such that further dose escalation would expose subjects to unacceptable risk; any Grade >=3 non-hematological toxicity except Grade 3 asymptomatic increases in liver function tests, diarrhea, nausea or vomiting with duration <= 48 hours and alopecia; Grade 4 neutropenia of >5 days duration or febrile neutropenia of >1 day duration; Grade 3 thrombocytopenia with bleeding or Grade 4 thrombocytopenia; any treatment interruption >2 weeks due to adverse events; any severe, impairing daily functions or life-threatening, complication or abnormality not defined in NCI-CTCAE that is attributable to the therapy. (NCT01378377)
Timeframe: Up to 21 Days (within Cycle 1)
| Intervention | subjects (Number) |
|---|---|
| Pimasertib 45 mg+Temsirolimus 12.5 mg | 0 |
| Pimasertib 45 mg+Temsirolimus 25 mg | 7 |
| Pimasertib 75 mg+Temsirolimus 25 mg | 2 |
An AE was defined as any new untoward medical occurrences/worsening of pre-existing medical condition, whether or not related to study drug. The TEAEs were those events that occur between first dose of trial treatment and up to 30 days after last dose of the trial treatment that were absent before treatment or that worsened relative to pretreatment state. (NCT01378377)
Timeframe: From the start of the trial treatment until data cut-off date (23 February 2012)
| Intervention | subjects (Number) |
|---|---|
| Pimasertib 45 mg+Temsirolimus 12.5 mg | 4 |
| Pimasertib 45 mg+Temsirolimus 25 mg | 23 |
| Pimasertib 75 mg+Temsirolimus 25 mg | 6 |
Clearance (CL) of a drug was a measure of the rate at which a drug was metabolized or eliminated by normal biological processes. The CL obtained after oral dose (CL/F) was influenced by the fraction of the dose absorbed (bioavailability). Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan. (NCT01378377)
Timeframe: DDI cohorts: Days 1 and 9 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1
| Intervention | liter/hour (Median) |
|---|---|
| Non-DDI: Day 8 | |
| Pimasertib 45 mg+Temsirolimus 25 mg (Non-DDI) | 64.31 |
| Pimasertib 75 mg+Temsirolimus 25 mg (Non-DDI) | 53.6 |
Clearance (CL) of a drug was a measure of the rate at which a drug was metabolized or eliminated by normal biological processes. The CL obtained after oral dose (CL/F) was influenced by the fraction of the dose absorbed (bioavailability). Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan. (NCT01378377)
Timeframe: DDI cohorts: Days 1 and 9 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1
| Intervention | liter/hour (Median) | |
|---|---|---|
| DDI: Day 1 | DDI: Day 9 | |
| Pimasertib 45 mg+Temsirolimus 12.5 mg (DDI) | 81.25 | 71.99 |
| Pimasertib 45 mg+Temsirolimus 25 mg (DDI) | 54.36 | 55.9 |
The t1/2 was defined as the time required for the plasma concentration of drug to decrease 50% in the final stage of its elimination. Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan. (NCT01378377)
Timeframe: DDI cohorts: Days 1 and 9 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1
| Intervention | hour (Median) |
|---|---|
| Non-DDI: Day 8 | |
| Pimasertib 45 mg+Temsirolimus 25 mg (Non-DDI) | 7.746 |
| Pimasertib 75 mg+Temsirolimus 25 mg (Non-DDI) | 5.712 |
The t1/2 was defined as the time required for the plasma concentration of drug to decrease 50% in the final stage of its elimination. Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan. (NCT01378377)
Timeframe: DDI cohorts: Days 1 and 9 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1
| Intervention | hour (Median) | |
|---|---|---|
| DDI: Day 1 | DDI: Day 9 | |
| Pimasertib 45 mg+Temsirolimus 12.5 mg (DDI) | 5.915 | 6.08 |
| Pimasertib 45 mg+Temsirolimus 25 mg (DDI) | 5.886 | 5.896 |
The t1/2 was defined as the time required for the plasma concentration of drug to decrease 50% in the final stage of its elimination. Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan. (NCT01378377)
Timeframe: DDI cohorts: Days 9 and 16 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1
| Intervention | hour (Median) |
|---|---|
| Non-DDI: Day 8 | |
| Pimasertib 45 mg+Temsirolimus 25 mg (Non-DDI) | 29.08 |
| Pimasertib 75 mg+Temsirolimus 25 mg (Non-DDI) | 10.42 |
The t1/2 was defined as the time required for the plasma concentration of drug to decrease 50% in the final stage of its elimination. Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan. (NCT01378377)
Timeframe: DDI cohorts: Days 9 and 16 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1
| Intervention | hour (Median) | |
|---|---|---|
| DDI: Day 9 | DDI: Day 16 | |
| Pimasertib 45 mg+Temsirolimus 12.5 mg (DDI) | 25.57 | 20.62 |
| Pimasertib 45 mg+Temsirolimus 25 mg (DDI) | 13.2 | 19.14 |
Volume of distribution (Vz) was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. The Vz after oral dose (Vz/F) was influenced by the fraction absorbed. Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan. (NCT01378377)
Timeframe: DDI cohorts: Days 1 and 9 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1
| Intervention | liter (Median) |
|---|---|
| Non-DDI: Day 8 | |
| Pimasertib 45 mg+Temsirolimus 25 mg (Non-DDI) | 760.6 |
| Pimasertib 75 mg+Temsirolimus (TEM) 25 mg (Non-DDI) | 416.5 |
Volume of distribution (Vz) was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. The Vz after oral dose (Vz/F) was influenced by the fraction absorbed. Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan. (NCT01378377)
Timeframe: DDI cohorts: Days 1 and 9 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1
| Intervention | liter (Median) | |
|---|---|---|
| DDI: Day 1 | DDI: Day 9 | |
| Pimasertib 45 mg+Temsirolimus 12.5 mg (DDI) | 691.3 | 517.6 |
| Pimasertib 45 mg+Temsirolimus 25 mg (DDI) | 536.5 | 519.5 |
The AUC(0-inf) was estimated by determining the total area under the curve of the concentration versus time curve extrapolated to infinity. Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan. (NCT01378377)
Timeframe: DDI cohorts: Days 9 and 16 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1
| Intervention | hour*nanogram/milliliter (Median) |
|---|---|
| Non-DDI: Day 8 | |
| Pimasertib 45 mg+Temsirolimus 25 mg (Non-DDI) | 4026 |
| Pimasertib 75 mg+Temsirolimus 25 mg (Non-DDI) | 2194 |
The AUC(0-inf) was estimated by determining the total area under the curve of the concentration versus time curve extrapolated to infinity. Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan. (NCT01378377)
Timeframe: DDI cohorts: Days 9 and 16 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1
| Intervention | hour*nanogram/milliliter (Median) | |
|---|---|---|
| DDI: Day 9 | DDI: Day 16 | |
| Pimasertib 45 mg+Temsirolimus 12.5 mg (DDI) | 2452 | 2006 |
| Pimasertib 45 mg+Temsirolimus 25 mg (DDI) | 2130 | 2743 |
The AUCtau was defined as the area under the concentration curve divided by the dosing interval. AUC(0-inf) was estimated by determining the total area under the curve of the concentration versus time curve extrapolated to infinity. Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan. (NCT01378377)
Timeframe: DDI cohorts: Days 9 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1 for AUCtau; DDI cohorts: Day 1 of Cycle 1 AUC0-inf
| Intervention | hour*nanogram/milliliter (Median) |
|---|---|
| Non-DDI: AUCtau: Day 8 | |
| Pimasertib 45 mg+Temsirolimus 25 mg (Non-DDI) | 706 |
| Pimasertib 75 mg+Temsirolimus 25 mg (Non-DDI) | 1402 |
The AUCtau was defined as the area under the concentration curve divided by the dosing interval. AUC(0-inf) was estimated by determining the total area under the curve of the concentration versus time curve extrapolated to infinity. Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan. (NCT01378377)
Timeframe: DDI cohorts: Days 9 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1 for AUCtau; DDI cohorts: Day 1 of Cycle 1 AUC0-inf
| Intervention | hour*nanogram/milliliter (Median) | |
|---|---|---|
| DDI: AUCtau: Day 9 | DDI: AUC0-inf: Day 1 | |
| Pimasertib 45 mg+Temsirolimus 12.5 mg (DDI) | 628 | 573.2 |
| Pimasertib 45 mg+Temsirolimus 25 mg (DDI) | 805 | 828.6 |
Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan. (NCT01378377)
Timeframe: Drug-drug interaction (DDI) cohorts: Days 1 and 9 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1
| Intervention | nanogram/milliliter (Median) |
|---|---|
| Non-DDI: Day 8 | |
| Pimasertib 45 mg+Temsirolimus 25 mg (Non-DDI) | 197.6 |
| Pimasertib 75 mg+Temsirolimus 25 mg (Non-DDI) | 308.1 |
Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan. (NCT01378377)
Timeframe: Drug-drug interaction (DDI) cohorts: Days 1 and 9 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1
| Intervention | nanogram/milliliter (Median) | |
|---|---|---|
| DDI: Day 1 | DDI: Day 9 | |
| Pimasertib 45 mg+Temsirolimus 12.5 mg (DDI) | 185.2 | 131 |
| Pimasertib 45 mg+Temsirolimus 25 mg (DDI) | 193.5 | 192.1 |
Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan. (NCT01378377)
Timeframe: DDI cohorts: Days 9 and 16 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 8
| Intervention | nanogram/milliliter (Median) |
|---|---|
| Non-DDI: Day 8 | |
| Pimasertib 45 mg+Temsirolimus 25 mg (Non-DDI) | 489.9 |
| Pimasertib 75 mg+Temsirolimus 25 mg (Non-DDI) | 480.9 |
Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan. (NCT01378377)
Timeframe: DDI cohorts: Days 9 and 16 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 8
| Intervention | nanogram/milliliter (Median) | |
|---|---|---|
| DDI: Day 9 | DDI: Day 16 | |
| Pimasertib 45 mg+Temsirolimus 12.5 mg (DDI) | 457.5 | 281.1 |
| Pimasertib 45 mg+Temsirolimus 25 mg (DDI) | 505.3 | 511.8 |
Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan. (NCT01378377)
Timeframe: DDI cohorts: Days 1 and 9 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1
| Intervention | hour (Median) |
|---|---|
| Non-DDI: Day 8 | |
| Pimasertib 45 mg+Temsirolimus 25 mg (Non-DDI) | 1.5 |
| Pimasertib 75 mg+Temsirolimus 25 mg (Non-DDI) | 0.5833 |
Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan. (NCT01378377)
Timeframe: DDI cohorts: Days 1 and 9 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1
| Intervention | hour (Median) | |
|---|---|---|
| DDI: Day 1 | DDI: Day 9 | |
| Pimasertib 45 mg+Temsirolimus 12.5 mg (DDI) | 1 | 2.3 |
| Pimasertib 45 mg+Temsirolimus 25 mg (DDI) | 1.5 | 1.133 |
Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan. (NCT01378377)
Timeframe: DDI cohorts: Days 9 and 16 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1
| Intervention | hour (Median) |
|---|---|
| Non-DDI: Day 8 | |
| Pimasertib 45 mg+Temsirolimus 25 mg (Non-DDI) | 0.5 |
| Pimasertib 75 mg+Temsirolimus 25 mg (Non-DDI) | 0.55 |
Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan. (NCT01378377)
Timeframe: DDI cohorts: Days 9 and 16 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1
| Intervention | hour (Median) | |
|---|---|---|
| DDI: Day 9 | DDI: Day 16 | |
| Pimasertib 45 mg+Temsirolimus 12.5 mg (DDI) | 0.7417 | 0.9333 |
| Pimasertib 45 mg+Temsirolimus 25 mg (DDI) | 0.5667 | 0.5 |
The clearance of a drug was a measure of the rate at which a drug was metabolized or eliminated by normal biological processes. Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan. (NCT01378377)
Timeframe: DDI cohorts: Days 9 and 16 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1
| Intervention | liter/hour (Median) |
|---|---|
| Non-DDI: Day 8 | |
| Pimasertib 45 mg+Temsirolimus 25 mg (Non-DDI) | 6.284 |
| Pimasertib 75 mg+Temsirolimus 25 mg (Non-DDI) | 11.39 |
The clearance of a drug was a measure of the rate at which a drug was metabolized or eliminated by normal biological processes. Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan. (NCT01378377)
Timeframe: DDI cohorts: Days 9 and 16 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1
| Intervention | liter/hour (Median) | |
|---|---|---|
| DDI: Day 9 | DDI: Day 16 | |
| Pimasertib 45 mg+Temsirolimus 12.5 mg (DDI) | 5.378 | 7.528 |
| Pimasertib 45 mg+Temsirolimus 25 mg (DDI) | 11.73 | 9.292 |
The Vz was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan. (NCT01378377)
Timeframe: DDI cohorts: Days 9 and 16 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1
| Intervention | liter (Median) |
|---|---|
| Non-DDI: Day 8 | |
| Pimasertib 45 mg+Temsirolimus 25 mg (Non-DDI) | 309.7 |
| Pimasertib 75 mg+Temsirolimus 25 mg (Non-DDI) | 172.9 |
The Vz was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan. (NCT01378377)
Timeframe: DDI cohorts: Days 9 and 16 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1
| Intervention | liter (Median) | |
|---|---|---|
| DDI: Day 9 | DDI: Day 16 | |
| Pimasertib 45 mg+Temsirolimus 12.5 mg (DDI) | 152 | 189.5 |
| Pimasertib 45 mg+Temsirolimus 25 mg (DDI) | 244.5 | 233 |
2 reviews available for niacinamide and Mucositis
| Article | Year |
|---|---|
Risk of mucocutaneous toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis.
Topics: Alopecia; Antineoplastic Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as T | 2014 |
Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Clinical | 2012 |
3 trials available for niacinamide and Mucositis
| Article | Year |
|---|---|
Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: a phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asth | 2013 |
Incidence of mucositis in patients treated with temsirolimus-based regimens and correlation to treatment response.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2014 |
Incidence of mucositis in patients treated with temsirolimus-based regimens and correlation to treatment response.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2014 |
Incidence of mucositis in patients treated with temsirolimus-based regimens and correlation to treatment response.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2014 |
Incidence of mucositis in patients treated with temsirolimus-based regimens and correlation to treatment response.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2014 |
Incidence of mucositis in patients treated with temsirolimus-based regimens and correlation to treatment response.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2014 |
Incidence of mucositis in patients treated with temsirolimus-based regimens and correlation to treatment response.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2014 |
Incidence of mucositis in patients treated with temsirolimus-based regimens and correlation to treatment response.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2014 |
Incidence of mucositis in patients treated with temsirolimus-based regimens and correlation to treatment response.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2014 |
Incidence of mucositis in patients treated with temsirolimus-based regimens and correlation to treatment response.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2014 |
Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment.
Topics: Adult; Aged; Aged, 80 and over; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Renal Cell; Diarrhe | 2012 |
2 other studies available for niacinamide and Mucositis
| Article | Year |
|---|---|
Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcin
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Databa | 2016 |
Sunitinib in metastatic renal cell carcinoma (mRCC): a developing country experience. Do our patients behave differently than the Western patients?
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents; Carcinoma, Renal Cell; Developing C | 2016 |